thyroid cancer
Genetron Health Adds New Assays to Pipeline While Anticipating MRD Launch, Liver Cancer Kit Trials
Premium
As it eyes new targets, the firm is poised to launch its personalized solid tumor MRD assay this year and is progressing toward approval for a liver cancer early detection IVD.
Interpace Biosciences Says CMS to Cover Thyroid Tests, Reversing Earlier Decision
CMS previously said it would no longer reimburse for the ThyGeNext and ThyraMir tests when the tests are billed together.
CMS No Longer Reimbursing Interpace Bio Thyroid Tests; Firm's Rights Offering Terminated
CMS has issued a new billing policy and will no longer reimburse for the use of Interpace's ThyGeNext and ThyraMir thyroid cancer tests under certain conditions.
Veracyte Q2 Revenues More Than Double on Test Volume Spike
The company's commercial test volume and test revenues were both up more than 200 percent compared to the same quarter last year.
Bayer, Veracyte to Identify Therapy-Resistant Thyroid Cancer Patients
Bayer will offer Veracyte's Afirma Xpression Atlas to identify underlying drivers in tumors of late-stage or metastatic thyroid cancer patients resistant to radioactive iodine therapy.